人β防御素-2通过TGF-β/Smad信号通路对胃癌SGC7901细胞增殖、迁移和侵袭的影响

该文探讨了人β防御素-2(hBD2)对胃癌SGC7901细胞的增殖、迁移和侵袭的影响。将真核表达载体pCMV-hBD2转染于人胃癌SGC7901细胞。采用qPCR和免疫印迹法(Western blot)检测转染效率。Western blot检测TGF-β1、p-Smad2/3、Smad2/3、MMP9的蛋白表达水平。Transwell法检测SGC7901细胞迁移和侵袭能力。EdU法和流式细胞术分别检测增殖能力与细胞周期。结果显示,转染真核表达载体pCMV-hBD2的SGC7901细胞, hBD2的表达水平明显高于SGC7901和转染pCMV-Blank的SGC7901细胞。SGC7901-hBD2细胞中TGF-β1、p-Smad2/3和MMP9的蛋白表达水平均低于SGC7901和SGC7901-Blank细胞,而Smad2/3表达水平不变。同时,其迁移侵袭和增殖能力均受到抑制,细胞周期G0/G1期阻滞。该实验结果表明, hBD2可能通过下调TGF-β/Smad信号通路调控SGC7901细胞的迁移侵袭以及增殖能力。     

LncRNA MIR4435-2HG调控miR-138-5p/HMGA1轴对胃癌细胞的增殖、侵袭和迁移的影响

目的 探讨LncRNA MIR4435-2HG对胃癌细胞增殖、侵袭和迁移的影响及作用机制.方法 培养正常人胃黏膜上皮细胞GES-1和胃癌细胞系AGS、SGC7901、BGC823和BGC803,AGS细胞分为对照组(正常培养细胞)、si-con组(转染乱序无意义阴性序列)、si-MIR4435-2HG组(转染MIR44...     

过表达P185可抑制EMT并促进胃癌细胞侵袭和迁移

为探究过表达P185基因对胃癌SGC7901细胞侵袭、迁移的影响以及可能作用机制,本研究通过脂质体将携带P185基因的过表达pcDNA3.1-P185质粒,转染至胃癌SGC7901细胞中;本研究采用qRT-PCR和免疫印迹试验(Western blotting)检测P185 mRNA的转录水平和蛋白水平,Western blotting检测钙黏蛋白E(E-cadherin)、波形蛋白(Vimentin)、基质金属蛋白酶-2 (matrix metalloprotease, MMP-2)表达;以Transwell小室法检测细胞的侵袭、迁移能力的变化。研究结果表明:胃癌细胞转染过表达pcDNA3.1-P185质粒能显著上调P185 mRNA和蛋白质的表达(p0.05);SGC7901细胞转染重组质粒pcDNA3.1-P185后,细胞的侵袭、迁移能力较对照组显著增强(p0.05),细胞中E-cadherin蛋白水平显著下调(p0.05),Vimentin、MMP-2蛋白水平显著增加(p0.05)。本研究显示P185可能通过抑制EMT,促进细胞外基质的降解、促进胃癌细胞的侵袭、迁移。     

迁移侵袭抑制蛋白抑制胃癌细胞增殖迁移及侵袭

目的检测迁移侵袭抑制蛋白(migration and invasion inhibi tory protein,MIIP)基因在胃癌中的表达情况及其在胃癌发生发展过程中起到的作用,为探究胃癌发生的分子机制和靶向治疗提供实验依据。方法 Western blot和免疫组织化学法检测MIIP在胃癌组织的表达。胃癌SGC7901细胞中转染MIIP过表达质粒及其空质粒,应用细胞功能学实验检测MIIP过表达对胃癌细胞增殖、迁移和侵袭能力的影响。结果 MIIP在胃癌组织标本中的表达低于癌旁正常胃粘膜;细胞功能实验结果显示,MIIP过表达可抑制胃癌细胞的增殖、迁移和侵袭能力。结论过表达MIIP可以抑制胃癌SGC7901细胞增殖、迁移和侵袭的能力。     

人多肽N-乙酰氨基半乳糖转移酶2基因反义RNA表达质粒的构建及其功能的初步研究

反义封闭人多肽N-乙酰氨基半乳糖转移酶2 (pp-GalNAc-T2)的基因表达, 对胃癌细胞SGC7901中转化生长因子-β1(TGF-β1)与基质金属蛋白酶2 (MMP2)基因表达及细胞增殖有影响.在对几株肿瘤细胞的pp-GalNAc-T2基因表达水平进行分析后, 以高表达pp-GalNAc-T2的人胃癌细胞株SGC7901的总RNA为模板, 利用RT-PCR方法扩增两段不同长度pp-GalNAc-T2基因片段, 构建反义表达载体转染胃癌细胞SGC7901, 通过Ｇ418筛选, 建立一系列旨在封闭胃癌细胞SGC7901 ppGalNAc-T2基因表达的亚细胞克隆.通过流式细胞术、荧光显微镜、RT-PCR及Western印迹检测反义封闭pp-GalNAc-T2基因RNA表达后胃癌细胞SGC7901增殖以及TGF-β1、MMP2表达水平的变化. 反义封闭pp-GalNAc-T2基因表达后, 胃癌细胞SGC7901 pp-GalNAc-T2的表达水平明显降低, 细胞分裂增殖减慢, 表明反义封闭pp-GalNAc-T2基因表达对胃癌细胞SGC7901的生长增殖有影响.结果还显示, 反义封闭pp-GalNAc-T2基因表达可使TGF-β1、MMP2基因在mRNA与蛋白质表达水平均增加, 提示pp-GalNAc-T2基因表达可能对胃癌细胞SGC7901浸润转移产生影响.以上结果表明, pp-GalNAc-T2基因在肿瘤细胞中广泛表达, 并可能与肿瘤的增殖及浸润转移相关.     

MiR-935通过其靶基因Notch1调控胃癌SGC7901细胞的发生发展

目的:探究Mi R-935调控胃癌SGC7901细胞的增殖和浸润与Notch1基因表达的关系。方法:分别检测40例正常人胃粘膜组织与40例胃印戒细胞癌的Notch1表达情况,并分析胃印戒细胞癌组织中Notch1表达与患者年龄、性别、组织进展程度、TNM分期、有无淋巴结转移的关系;采用Mi R-935转染体外培养的SGC7901细胞系,检测Notch1的表达情况,其后采用Mi R-935抑制剂处理,通过Transwell实验检测胃癌细胞的侵袭能力,细胞划痕实验检测胃癌细胞迁移能力。结果:正常人胃粘膜组织中Notch1表达呈阴性,而胃印戒细胞癌组织中Notch1表达呈阳性;Notch1的表达与胃印戒细胞癌的TNM分期、有无淋巴结转移存在着显著的相关性;转染Mi R-935的SGC7901细胞Notch1表达明显上调,采用Mi R-935抑制剂处理后,Notch1的表达显著下降。结论:Mi R-935可能通过调控Notch1的表达调控胃癌的扩增和浸润。     

DDX20基因对胃癌细胞迁移能力的调控作用

目的:基于细胞划痕实验研究DDX20基因对胃癌细胞迁移能力的调控作用。方法:首先采用实时定量PCR检测人胃黏膜细胞GES,胃癌细胞MGC803、SGC7901和MKN74中DDX20基因的表达水平,确定DDX20基因高表达和低表达细胞株;进而针对DDX20基因设计并包装过表达及干扰慢病毒,基于实时定量PCR和Western印迹筛选稳定转染细胞株;基于稳定转染细胞株进行细胞划痕实验并采集图片。结果:与正常的胃黏膜细胞GES相比,DDX20基因在MGC803胃癌细胞中表达水平最高,在MKN74胃癌细胞中表达水平次之,在SGC7901胃癌细胞中表达水平最低。转染DDX20过表达慢病毒后,DDX20基因及蛋白表达水平显著增加;转染DDX20干扰慢病毒,特别是sh-RNA-02干扰慢病毒后,DDX20基因及蛋白表达水平显著降低。过表达DDX20基因能显著促进胃癌细胞的迁移,抑制DDX20基因的表达可显著降低胃癌细胞的迁移。结论:DDX20基因是一个肿瘤转移相关基因,通过抑制该基因的表达能有效降低细胞的迁移,为胃癌的临床治疗提供了一个潜在靶点,具有一定的临床应用价值。     

温热抑制人胃癌SGC7901细胞增殖、迁移

目的探讨温热对人胃癌SGC790l细胞增殖、迁移的影响。方法对照组常温(37℃)下培养人胃癌SGC790l细胞,实验组43℃水浴加热0.5h、1h、2h、3h后培养24h,采用倒置显微镜观察胃癌细胞的形态结构变化;Hoechst-33258荧光染色观察细胞核的变化;四甲基偶氮唑盐比色法(MTT)检测细胞增殖抑制;细胞划痕愈合实验观察温热对胃癌细胞的运动迁移能力的影响;体外细胞侵袭实验(Transwell实验)观察温热对胃癌细胞侵袭能力的影响。结果温热后细胞明显皱缩、变圆及细胞漂浮,3h大部分细胞漂浮;荧光染色显示温热后部分细胞核内出现浓染致密的颗粒块状荧光,胞核固缩、染色质高度凝聚和碎裂;MTT实验提示温热可明显抑制SGC790l细胞生长;细胞划痕实验发现SGC790l细胞温热1h、2 h后细胞迁移距离均明显小于对照组,温热3h后细胞基本未发生迁移;Transwell实验提示SGC790l细胞温热后细胞侵袭能力明显下降。结论温热对胃癌SGC790l细胞具有明显的杀伤作用,温热可明显抑制胃癌SGC790l细胞增殖和侵袭迁移能力。     

DDX20基因对胃癌细胞迁移能力的调控作用

基于细胞划痕实验研究了DDX20基因对胃癌细胞迁移能力的调控作用。首先采用实时定量PCR检测人胃粘膜细胞GES、胃癌细胞MGC803、SGC7901和MKN74中DDX20基因的表达水平,确定DDX20基因高表达和低表达细胞株;进而针对DDX20基因设计、包被过表达并干扰慢病毒,基于实时定量PCR和Western Blot筛选稳定转染细胞株;基于稳定转染细胞株进行细胞划痕实验并采集图片。结果显示,与正常的胃粘膜细胞GES相比,DDX20基因在MGC803胃癌细胞中表达水平最高、MKN74胃癌细胞中表达水平次之、SGC7901胃癌细胞中表达水平最低。转染DDX20过表达慢病毒后,DDX20基因及蛋白表达水平显著增加;转染DDX20干扰慢病毒后,DDX20基因及蛋白表达水平显著降低,特别是转染干扰组2干扰慢病毒。过表达DDX20基因能显著促进胃癌细胞的迁移,抑制DDX20基因的表达可显著降低胃癌细胞的迁移。结果表明,DDX20基因是一个肿瘤转移相关基因,通过抑制该基因的表达能有效降低肿瘤细胞的迁移,为胃癌的临床治疗提供了一个潜在靶点,具有一定的临床应用价值。     

Sprouty-2对胃癌细胞上皮间质转化及侵袭转移的影响

目的:研究Sprouty2(SPRY2)基因在胃癌肿瘤细胞上皮间质转化(EMT)和侵袭转移的影响。方法:体外培养人胃癌细胞(BGC-823),采用慢病毒介导的sh RNA沉默SPRY2基因,并用实时定量PCR与Western blot检测其SPRY2、E-钙黏蛋白(E-cadherin)、波形蛋白(vimentin)的表达,采用细胞划痕实验、Transwell实验检测SPRY2基因沉默后的胃癌细胞侵袭转移能力变化。结果:在慢病毒介导sh RNA沉默SPRY2基因的人胃癌BGC-823细胞中,SPRY2的m RNA和蛋白表达明显降低(P0.05),SPRY2沉默后人胃癌细胞E-cadherin的蛋白表达增多(P0.05),vimentin的蛋白表达减少(P0.05)。此外,SPRY2沉默后,胃癌细胞迁移能力和侵袭能力明显减弱(P值均P0.05)。结论:Sprouty-2基因通过调节E-cadherin与vimentin的表达参与胃癌细胞的上皮-间质转化,进而促进胃癌细胞的迁移与侵袭。     

Inflammation and Cancer: Role of Annexin A1 and FPR2/ALX in Proliferation and Metastasis in Human Laryngeal Squamous Cell Carcinoma

The anti-inflammatory protein annexin A1 (ANXA1) has been associated with cancer progression and metastasis, suggesting its role in regulating tumor cell proliferation. We investigated the mechanism of ANXA1 interaction with formylated peptide receptor 2 (FPR2/ALX) in control, peritumoral and tumor larynx tissue samples from 20 patients, to quantitate the neutrophils and mast cells, and to evaluate the protein expression and co-localization of ANXA1/FPR2 in these inflammatory cells and laryngeal squamous cells by immunocytochemistry. In addition, we performed in vitro experiments to further investigate the functional role of ANXA1/FPR2 in the proliferation and metastasis of Hep-2 cells, a cell line from larynx epidermoid carcinoma, after treatment with ANXA1_2–26 (annexin A1 N-terminal-derived peptide), Boc2 (antagonist of FPR) and/or dexamethasone. Under these treatments, the level of Hep-2 cell proliferation, pro-inflammatory cytokines, ANXA1/FPR2 co-localization, and the prostaglandin signalling were analyzed using ELISA, immunocytochemistry and real-time PCR. An influx of neutrophils and degranulated mast cells was detected in tumor samples. In these inflammatory cells of peritumoral and tumor samples, ANXA1/FPR2 expression was markedly exacerbated, however, in laryngeal carcinoma cells, this expression was down-regulated. ANXA1_2–26 treatment reduced the proliferation of the Hep-2 cells, an effect that was blocked by Boc2, and up-regulated ANXA1/FPR2 expression. ANXA1_2–26 treatment also reduced the levels of pro-inflammatory cytokines and affected the expression of metalloproteinases and EP receptors, which are involved in the prostaglandin signalling. Overall, this study identified potential roles for the molecular mechanism of the ANXA1/FPR2 interaction in laryngeal cancer, including its relationship with the prostaglandin pathway, providing promising starting points for future research. ANXA1 may contribute to the regulation of tumor growth and metastasis through paracrine mechanisms that are mediated by FPR2/ALX. These data may lead to new biological targets for therapeutic intervention in human laryngeal cancer.     

Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination

To identify proteins involved in melanoma metastasis mechanisms, comparative proteomic studies were undertaken on B16F10 and B16Bl6 melanoma cell lines and their subsequent syngenic primary tumours as pulmonary metastases were present only in the mice bearing a B16Bl6 tumour. 2DE analyses followed by MALDI-TOF identification showed variations of 6 proteins in vitro and 13 proteins in vivo. Differential expressed proteins in tumours were related to energy production and storage. Two differentially expressed proteins which had not been previously associated to melanoma progression, annexin A1 (ANXA1) and creatine kinase B (CKB), were found both in cells and in tumours. To characterize ANXA1 involvement in melanoma B16 dissemination, we reduced ANXA1 protein level by siRNA and observed a significant decrease of B16Bl6 cell invasion through Matrigel coated chambers. We further demonstrated that the presence of several formyl peptide receptors (FPR1, FPRrs1 and 2) revealed by qRT-PCR, played a role in B16 invasion: incubation of B16Bl6 cells with the FPR agonist (fMLP) or antagonist (tBOC) enhanced or decreased Matrigel coated chamber invasion respectively, with a correlation of ANXA1 levels in both treatments. As ANXA1 could bind to FPRs, this should amplify invasion and enhance melanoma dissemination.     

MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer

Background

MicroRNAs (miRNAs) are important regulators that play key roles in tumorigenesis and tumor progression. A previous report has shown that let-7 family members can act as tumor suppressors in many cancers. Through miRNA array, we found that let-7f was downregulated in the highly metastatic potential gastric cancer cell lines GC9811-P and SGC7901-M, when compared with their parental cell lines, GC9811 and SGC7901-NM; however, the mechanism was not clear. In this study, we investigate whether let-7f acts as a tumor suppressor to inhibit invasion and metastasis in gastric cancers.

Methodology/Principal

Real-time PCR showed decreased levels of let-7f expression in metastatic gastric cancer tissues and cell lines that are potentially highly metastatic. Cell invasion and migration were significantly impaired in GC9811-P and SGC7901-M cell lines after transfection with let-7f-mimics. Nude mice with xenograft models of gastric cancer confirmed that let-7f could inhibit gastric cancer metastasis in vivo after transfection by the lentivirus pGCsil-GFP- let-7f. Luciferase reporter assays demonstrated that let-7f directly binds to the 3′UTR of MYH9, which codes for myosin IIA, and real-time PCR and Western blotting further indicated that let-7f downregulated the expression of myosin IIA at the mRNA and protein levels.

Conclusions/Significance

Our study demonstrated that overexpression of let-7f in gastric cancer could inhibit invasion and migration of gastric cancer cells through directly targeting the tumor metastasis-associated gene MYH9. These data suggest that let-7f may be a novel therapeutic candidate for gastric cancer, given its ability to reduce cell invasion and metastasis.     

下调UCA1通过靶向miR-23b及其下游靶基因抑制胃癌细胞的增殖和转移

摘要 目的：探讨长链非编码RNA尿路上皮癌相关基因1（UCA1）调控胃癌细胞增殖和转移的分子机制。方法：将人胃癌细胞株SGC7901分为：对照组、siRNA-NC组、siRNA-UCA1组、inhibitor-NC组和miR-inhibitor组、si-UCA1+inhibitor-NC组和si-UCA1+miR-inhibitor组。对SGC7901细胞分别转染siRNA-UCA1及阴性对照（siRNA-NC）、miR-inhibitor及阴性对照（inhibitor-NC）,未转染的细胞作为对照组。通过RT-qPCR检测细胞中UCA1和miR-23b-3p的水平。通过CCK-8法、伤口愈合实验和Transwell实验评价细胞的增殖、迁移和侵袭能力。通过Western blot分析细胞中IL6R、BCL2和HSP90B1蛋白的表达。使用pcDNA-UCA1/pcDNA-NC与pGL3-miR-23b-3p-WT/pGL3-miR-23b-3p-Mut共转染细胞,通过双荧光素酶报告实验验证UCA1与miR-23b-3p的靶向关系。结果：细胞培养48 h和72 h后,与对照组比较,siRNA-UCA1组的细胞活力分别降低了31.58%和31.40%（P<0.05）。与对照组比较,siRNA-UCA1组的细胞迁移率[(61.46±5.43)% vs (23.16±3.17)%]、侵袭细胞数量（109.17±9.66 vs 50.83±6.96）、IL6R、BCL2和HSP90B1的蛋白相对表达量均显著降低,而miR-23b-3p相对表达量升高（P<0.05）。与pGL3-miR-23b-3p-WT共转染后,与pcDNA-NC组比较,pcDNA-UCA1组的相对荧光酶活性降低了66.12%（P<0.05）。与si-UCA1+inhibitor-NC组比较,si-UCA1+miR-inhibitor组的细胞活力、细胞迁移率、侵袭细胞数量、IL6R、BCL2和HSP90B1的蛋白相对表达量均显著升高（P<0.05）。结论：下调UCA1通过靶向miR-23b-3p及其下游基因IL6R、BCL2和HSP90B1来抑制胃癌细胞的增殖和转移。     

Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis

Ribosomal proteins (RP) S13 and RPL23 were previously identified as two upregulated genes in a multidrug-resistant gastric cancer cell line SGC7901/VCR compared to its parental cell SGC7901 by differential display PCR. The aim of this study was to explore the roles of RPS13 and RPL23 in multidrug resistance (MDR) in gastric cancer cells. RPS13 and RPL23 were genetically overexpressed in SGC7901 cells, respectively. Either RPS13 or RPL23 enhanced resistance of SGC7901 cells to vincristine, adriamycin, and 5-fludrouracil. RPL23 also enhanced resistance of SGC7901 cells to cisplatin. Overexpression of either RPS13 or RPL23 did not alter the population doubling time, [³H]leucine incorporation, and intracellular adriamycin accumulation of SGC7901 cells. However, either RPS13 or RPL23 could protect SGC7901 cells from undergoing vincristine-induced apoptosis. Western blot analysis revealed that both RPS13 and RPL23 significantly increased the expression level of Bcl-2 and Bcl-2/Bax ratio in SGC7901 cells. In addition, overexpression of RPL23 enhanced glutathione S-transferase (GST) activity and intracellular glutathione content in SGC7901 cells. Together, this work demonstrates that either RPS13 or RPL23 can promote MDR in gastric cancer cells by suppressing drug-induced apoptosis, and that RPL23 may also promote MDR in gastric cancer cells through regulation of glutathione S-transferase-mediated drug-detoxifying system.     

Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo

To investigate reversal effects of pantoprazole (PPZ) on multidrug resistance (MDR) in human gastric adenocarcinoma cells in vivo and in vitro. Human gastric adenocarcinoma cell SGC7901 was cultured in RPMI‐1640 medium supplemented with 10% fetal bovine serum and antibiotics in a humidified 5% CO₂ atmosphere at 37°C. Adriamycin (ADR)‐resistant cells were cultured with addition of 0.8 µg/ml of ADR maintaining MDR phenotype. ADR was used to calculate ADR releasing index; CCK‐8 Assay was performed to evaluate the cytotoxicity of anti‐tumor drugs; BCECF‐AM pH‐sensitive fluorescent probe was used to measure intracellular pH (pHi) value of cells, whereas pH value of medium was considered as extracellular pH (pHe) value; Western blotting and immunofluorescent staining analyses were employed to determine protein expressions and intracellular distributions of vacuolar H⁺‐ATPases (V‐ATPases), mTOR, HIF‐1α, P‐glycoprotein (P‐gp), and multidrug resistant protein 1 (MRP1); SGC7901 and SGC7901/ADR cells were inoculated in athymic nude mice. Thereafter, effects of ADR with or without PPZ pretreatment were compared by determining the tumor size and weight, apoptotic cells in tumor tissues were detected by TUNEL assay. At concentrations greater than 20 µg/ml, PPZ pretreatment reduced ADR releasing index and significantly enhanced intracellular ADR concentration of SGC7901 (P < 0.01). Similarly, PPZ pretreatment significantly decreased ADR releasing index of SGC7901/ADR dose‐dependently (P < 0.01). PPZ pretreatment also decreased cell viabilities of SGG7901 and SGC7901/ADR dose‐dependently. After 24‐h PPZ pretreatment, administration of chemotherapeutic agents demonstrated maximal cytotoxic effects on SGC7901 and SGC7901/ADR cells (P < 0.05). The resistance index in PPZ pretreatment group was significantly lower than that in non‐PPZ pretreatment group (3.71 vs. 14.80). PPZ at concentration >10 µg/ml significantly decreased pHi in SGC7901 and SGC7901/ADR cells and diminished or reversed transmembrane pH gradient (P < 0.05). PPZ pretreatment also significantly inhibited protein expressions of V‐ATPases, mTOR, HIF‐1α, P‐gp, and MRP1, and alter intracellular expressions in parent and ADR‐resistant cells (P < 0.05). In vivo experiments further confirmed that PPZ pretreatment could enhance anti‐tumor effects of ADR on xenografted tumor of nude mice and also improve the apoptotic index in xenografted tumor tissues. PPZ pretreatment enhances the cytotoxic effects of anti‐tumor drugs on SGC7901 and reverse MDR of SGC7901/ADR by downregulating the V‐ATPases/mTOR/HIF‐1α/P‐gp and MRP1 signaling pathway. J. Cell. Biochem. 113: 2474–2487, 2012. © 2012 Wiley Periodicals, Inc.     

幽门螺杆菌感染性胃癌组织中cyclinD1、MMP-9的表达及其临床意义

目的:探讨幽门螺杆菌(HP)感染性胃癌组织中细胞周期蛋白D1(cyclinD1)、基质金属蛋白酶-9(MMP-9)的表达及其临床意义。方法:选取2016年12月到2018年6月期间在兰州大学第一医院接受治疗的胃癌患者80例,收集其手术切除的病理组织。采用C-14呼气试验和改良Giemsa染色检测患者HP感染的情况,采用免疫组化法检测胃癌组织中cyclinD1、MMP-9表达情况。分析HP感染、cyclinD1、MMP-9表达与胃癌患者临床病理特征的关系,并分析胃癌患者HP感染与cyclinD1、MMP-9表达的相关性。结果:80例胃癌患者HP感染阳性56例(70.00%),阴性24例(30.00%)。有淋巴结转移、浸润深度为T3+T4的胃癌患者的HP感染阳性率高于无淋巴结转移、浸润深度为T1+T2的胃癌患者(P0.05)。80例胃癌患者cyclinD1阳性表达45例(56.25%),阴性表达35例(43.75%),MMP-9阳性表达65例(81.25%),阴性表达15例(18.75%),TNM临床分期为III+IV期、分化程度为低分化、有淋巴结转移、浸润深度为T3+T4的胃癌患者的cyclinD1、MMP-9阳性表达率明显高于TNM临床分期为I+II期、分化程度为中高分化、无淋巴结转移、浸润深度为T1+T2的胃癌患者(P0.05)。HP感染阳性患者的cyclinD1阳性表达率和MMP-9阳性表达率均明显高于HP感染阴性患者(P0.05)。Pearson相关分析显示,胃癌患者HP感染与cyclinD1、MMP-9表达均呈正相关(P0.05)。结论:胃癌患者的HP感染情况与淋巴结转移、浸润深度有关,cyclinD1和MMP-9的表达与TNM临床分期、分化程度、淋巴结转移、浸润深度有关,且胃癌患者HP感染与cyclinD1、MMP-9表达均呈正相关。     

长链非编码RNA UCA1在胃癌多药耐药中的作用研究

目的:研究胃癌耐药细胞及其亲本细胞中长链非编码RNA UCA1的表达差异,探讨UCA1在胃癌多药耐药中的作用。方法:通过实时荧光定量PCR(q RT-PCR)检测胃癌耐药细胞SGC7901/ADR、SGC7901/VCR及其亲本细胞SGC7901中UCA1的表达差异;通过si RNA转染降低SGC7901/ADR中UCA1表达,MTT法检测细胞半数抑制浓度(IC50)的变化,流式细胞仪检测细胞凋亡变化。结果:QRT-PCR结果显示,UCA1在SGC7901/ADR和SGC7901/VCR胃癌耐药细胞表达显著高于SGC7901胃癌亲本细胞;MTT实验表明,干扰UCA1的SGC7901/ADR相对于阴性对照(NC)组的IC50显著降低;凋亡检测结果显示,在相同剂量化疗药物作用下,干扰UCA1后SGC7901/ADR凋亡率显著高于NC组;Western blot证实,干扰UCA1表达可显著降低BCL-2蛋白表达。结论:长链非编码RNA UCA1在胃癌耐药细胞表达显著升高,干扰UCA1表达可明显逆转胃癌耐药,UCA1可作为治疗胃癌耐药的重要分子靶标。